Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know

Source Tradingkey

Amgen Inc (AMGN) closed down by 3.38%. The Pharmaceuticals & Medical Research sector is down by 1.51%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Eli Lilly and Co (LLY) down 0.62%; Moderna Inc (MRNA) down 1.89%; Johnson & Johnson (JNJ) down 2.30%.

What is driving Amgen Inc (AMGN)’s stock price down today?

Amgen experienced notable intraday volatility and downward pressure as market participants engaged in profit-taking following a substantial rally that had driven the equity toward multi-year highs. After trading near the upper end of its valuation range in preceding sessions, the stock faced recalibration from institutional investors weighing intrinsic cash flow projections against elevated valuation multiples. Broad market dynamics, including sector rotations within healthcare and biotechnology, further compounded the session's selling activity as traders adjusted short-term exposure across defensive assets.

While the company continues to advance key clinical initiatives, including recent positive late-stage readouts for its immunology candidate dazodalibep and pediatric study completions for Otezla, investor focus remains intensely fixated on high-stakes pipeline assets. In a hyper-competitive obesity landscape, clinical trial timelines and evidence thresholds for key candidates such as MariTide mean that any interim pause in fundamental catalysts can prompt institutional caution. Consequently, incremental clinical pipeline news proved insufficient to offset general profit-taking across the drug manufacturing complex during the session.

Fundamental performance remains anchored by strong commercial volume growth in core products such as Repatha and Evenity, which continue to generate robust free cash flow. However, long-term operational headwinds continue to create friction, including biosimilar competition against legacy franchises and pricing pressure associated with regulatory price settings under federal legislation. Combined with a significant debt load carried on the balance sheet, these structural factors have led market participants to demand a higher margin of safety, driving the pullback as investors weigh baseline commercial strength against future execution risks.

Technical Analysis of Amgen Inc (AMGN)

Technically, Amgen Inc (AMGN) shows a MACD (12,26,9) value of 5.033, indicating a neutral signal. The RSI at 50.194 suggests neutral condition and the Williams %R at 37.061 suggests buy condition. Please monitor closely.

SentimentAnalysis

Fundamental Analysis of Amgen Inc (AMGN)

Amgen Inc (AMGN) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $36.75B, ranking 14 in the industry. The net profit is $7.71B, ranking 10 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Hold, with an average price target of $392.30, a high of $500.00, and a low of $225.00.

More details about Amgen Inc (AMGN)

Company Specific Risks:

Pipeline Spillover from Cardiovascular Trial Setback: Recent Phase III clinical trial failures for competitor Lp(a)-lowering therapies have cast significant doubt on Amgen's key cardiovascular candidate, olpasiran, driving institutional downgrades and raising clinical risk for its ongoing OCEAN outcomes trials.
Institutional Downgrades and Delayed Pipeline Monetization: Wall Street firms, including HSBC and BMO Capital Markets, downgraded Amgen citing limited near-term valuation upside, as major potential growth catalysts—including obesity asset MariTide and olpasiran—are back-ended to late 2027 while near-term revenue growth remains capped in low single digits.
Biosimilar Competition and Patent Cliff Pressures: Amgen faces mounting top-line erosion as key blockbuster legacy products, including Prolia, Xgeva, Enbrel, and Otezla, encounter price discounting and biosimilar market entry, putting more than one-third of total company revenues at long-term risk.
Substantial Leverage and Debt Service Burden: Carrying approximately $57.3 billion in total debt against $14.0 billion in cash and cash equivalents, Amgen maintains a heavily leveraged balance sheet that restricts capital allocation flexibility and magnifies intraday vulnerability to potential earnings or pipeline misses.

Source

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

October hike odds climb toward 60% as Goldman and BofA both flip — what Warsh's "dose of accommodation" really changed Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Author Irene Q.

Sep 23, Wed

Rate futures now price roughly 55% to 62% for a 25bp hike at the October 27-28 FOMC, up from about 30% before Chair Warsh's post-meeting framing that the Fed is merely "removing some accommodation." Goldman Sachs has added an October hike to its forecast and Bank of America now sees moves in both October and December. Here is the repricing, the language behind it, and the two data points that decide it.

Four jobs reports in five days: what JOLTS, ADP, claims and the September payrolls mean for the October Fed decision The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.

Author Mitrade

Sep 28, Mon

The US labour market faces its densest data week of the month. JOLTS job openings land Tuesday (7.2 million expected), ADP on Wednesday (70,000 expected), initial claims on Thursday and the September non-farm payrolls on Friday (100,000 expected, down from 162,000). Markets price a 64%-70% chance of another quarter-point Fed hike on October 28. The dollar index sits at 100.77 and the S&P 500 at 7,729.8.

Nvidia's $150 billion buyback landed — and the AI sector fell anyway. That's the signal worth trading Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

Author Irene Q.

Sep 29, Tue

Nvidia closed up 1.68% at $228.86 on 28 September after announcing a $150 billion share repurchase authorisation, the largest single corporate buyback on record, while the rest of the AI complex sold off: AMD -3.6%, Micron -2.6%, Meta -4.8% and the Philadelphia Semiconductor Index -1.61%. The divergence is not noise. Capital is rotating toward cash-flow certainty, not abandoning the AI theme. With Micron reporting after the close on 30 September, here is what the split means.

【Daily Brief】30-year Treasury tops 5.59%, S&P 500 slips to 7,670 and gold holds $4,180 — PCE lands tonight The 30-year Treasury yield closed at 5.59%, its highest since June 2002, and the Dow fell 131.59 points to 51,349.92. US consumer confidence dropped to 81.9, a 12-year low, and JOLTS job openings fell to 7.1 million. August PCE and Q3 GDP both land at 8:30am ET tonight.

Author Suzie

Sep 30, Wed

The 30-year Treasury yield closed at 5.59%, its highest since June 2002, and the Dow fell 131.59 points to 51,349.92. US consumer confidence dropped to 81.9, a 12-year low, and JOLTS job openings fell to 7.1 million. August PCE and Q3 GDP both land at 8:30am ET tonight.

Gold falls to near $4,150 as higher Treasury yields, oil prices outweigh softer PCE inflation Gold price (XAU/USD) tumbles to near $4,150 during the early Asian session on Thursday, pressured by elevated US Treasury bond yields. Traders await the US September employment data for fresh impetus, which will be released later on Friday.

Author FXStreet

Yesterday 01: 26

Gold price (XAU/USD) tumbles to near $4,150 during the early Asian session on Thursday, pressured by elevated US Treasury bond yields. Traders await the US September employment data for fresh impetus, which will be released later on Friday.

Popular Symbols